6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
occurring O
at O
least O
3 O
% O
more O
frequently O
than O
on O
placebo O
are O
mild O
local O
reactions O
at O
the O
site O
of O
injection O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Merz O
North O
America O
, O
Inc O
. O
at O
1-866-862-1211 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Study O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
5 O
controlled O
randomized O
clinical O
trials O
, O
Asclera O
has O
been O
administered O
to O
401 O
patients O
with O
small O
or O
very O
small O
varicose B-Not_AE_Candidate
veins I-Not_AE_Candidate
( O
reticular B-Not_AE_Candidate
and O
spider O
veins I-Not_AE_Candidate
) O
and O
compared O
with O
another O
sclerosing O
agent O
and O
with O
placebo O
. O

Patients O
were O
18 O
to O
70 O
years O
old O
. O

The O
patient O
population O
was O
predominately O
female O
and O
consisted O
of O
Caucasian O
and O
Asian O
patients O
. O

Table O
1 O
shows O
adverse O
events O
more O
common O
with O
Asclera O
or O
sodium O
tetradecyl O
sulfate O
( O
STS O
) O
1 O
% O
than O
with O
placebo O
by O
at O
least O
3 O
% O
in O
the O
placebo- O
controlled O
EASI O
study O
( O
see O
Clinical O
Studies O
[ O
14 O
] O
) O
. O

All O
of O
these O
were O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
most O
were O
mild O
. O

Table O
1 O
: O
Adverse O
Reactions O
in O
EASI-study O
ASCLERA O
( O
180 O
patients O
) O
STS O
1 O
% O
( O
105 O
patients O
) O
Placebo O
( O
53 O
patients O
) O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
haematoma I-OSE_Labeled_AE
42 O
% O
65 O
% O
19 O
% O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
41 O
% O
73 O
% O
30 O
% O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
38 O
% O
74 O
% O
4 O
% O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
24 O
% O
31 O
% O
9 O
% O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pruritus I-OSE_Labeled_AE
19 O
% O
27 O
% O
4 O
% O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
warmth I-OSE_Labeled_AE
16 O
% O
21 O
% O
6 O
% O
Neovascularisation B-OSE_Labeled_AE
8 O
% O
20 O
% O
4 O
% O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
6 O
% O
1 O
% O
0 O
% O
Ultrasound O
examinations O
at O
one O
week O
( O
+/-3 O
days O
) O
and O
12 O
weeks O
( O
+/-2 O
weeks O
) O
after O
treatment O
did O
not O
reveal O
deep B-NonOSE_AE
vein I-NonOSE_AE
thrombosis I-NonOSE_AE
in O
any O
treatment O
group O
. O

6.2 O
Post-marketing O
Safety O
Experience O
The O
following O
adverse O
reactions O
have O
been O
reported O
during O
use O
of O
polidocanol O
in O
world-wide O
experience O
; O
in O
some O
of O
these O
cases O
these O
adverse O
events O
have O
been O
serious O
or O
troublesome O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
and O
without O
a O
control O
group O
, O
it O
is O
not O
possible O
to O
estimate O
their O
frequency O
reliably O
or O
to O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Anaphylactic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
generalized O
, O
asthma B-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
( O
local O
) O
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
Cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
palpitations B-OSE_Labeled_AE
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
vasovagal I-OSE_Labeled_AE
, O
circulatory B-OSE_Labeled_AE
collapse I-OSE_Labeled_AE
, O
vasculitis B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
Dyspnea B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Skin B-OSE_Labeled_AE
hyperpigmentation I-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
, O
hypertrichosis B-OSE_Labeled_AE
( O
in O
the O
area O
of O
sclerotherapy O
) O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
injection I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
: O
Nerve B-OSE_Labeled_AE
injury I-OSE_Labeled_AE

